Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?
Open Access
- 8 August 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 953716
Abstract
Immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder featured by increased platelet destruction and deficient megakaryocyte maturation. First-line treatments include corticosteroids, intravenous immunoglobulin and intravenous anti-D immunoglobulin. Second-line treatments consist of rituximab, thrombopoietin receptor agonists and splenectomy. Although most patients benefit from these treatments, an individualized treatment approach is warranted due to the large heterogeneity among ITP patients. In addition, ITP patients may relapse and there remains a subset of patients who become refractory to treatments. The management of these refractory patients is still a challenge. This review aims to summarize emerging therapeutic approaches for refractory ITP in several categories according to their different targets, including macrophages, platelets/megakaryocytes, T cells, B cells, and endothelial cells. Moreover, current management strategies and combination regimens of refractory ITP are also discussed.Keywords
This publication has 119 references indexed in Scilit:
- Rozrolimupab, a first-in-class recombinant monoclonal antibody product for primary immune thrombocytopaeniaExpert Opinion on Biological Therapy, 2013
- B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cellsJournal of Clinical Investigation, 2012
- Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in miceArthritis Research & Therapy, 2012
- Megakaryocytes, malignancy and bone marrow vascular nichesJournal of Thrombosis and Haemostasis, 2011
- Stimulation of the PD-1/PDL-1 T-cell co-inhibitory pathway is effective in treatment of experimental autoimmune glomerulonephritisNephrology Dialysis Transplantation, 2011
- Platelets, Petechiae, and Preservation of the Vascular WallNew England Journal of Medicine, 2008
- Decreased DNA Methyltransferase 3A and 3B mRNA Expression in Peripheral Blood Mononuclear Cells and Increased Plasma SAH Concentration in Adult Patients with Idiopathic Thrombocytopenic PurpuraJournal of Clinical Immunology, 2008
- Fc receptors in immune thrombocytopenias: a target for immunomodulation?Journal of Clinical Investigation, 2008
- Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levelsNature Biotechnology, 2005
- Treatment of Refractory Immune Thrombocytopenic Purpura with an Anti-Fcγ-Receptor AntibodyNew England Journal of Medicine, 1986